Physician profile
Molham Aldeiri
NPI 1356586994
$13,972.04
in general payments reported to CMS, 2019-2025
53 companies · $3,178 in 2025
The $3,178 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,482 · 2020: $702 · 2021: $819 · 2022: $3,620 · 2023: $1,605 · 2024: $2,565 · 2025: $3,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,347.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,284.44 | 2019-2025 | Diamondback Peripheral, Navitor, Xact |
| Boston Scientific Corporation | $3,009.66 | 2019-2025 | Emblem Mri S-Icd, Watchman Flx, Watchman Access System |
| Abiomed | $1,570.19 | 2019-2025 | Impella |
| Medtronic, INC. | $920.67 | 2021-2025 | Corevalve Evolut R, Concertotm, In.Pact Admiral |
| Edwards Lifesciences Corporation | $742.99 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $409.43 | 2022-2025 | Verquvo, Capvaxive |
| Impulse Dynamics (USA) INC. | $407.94 | 2022-2024 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $299.08 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $287.98 | 2019-2025 | |
| Novo Nordisk INC | $214.88 | 2024-2025 | Wegovy, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.14 | 2019-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $197.69 | 2024-2025 | Uptravi, Opsumit |
| Medtronic Vascular, INC. | $163.44 | 2020 | |
| Amgen INC. | $158.70 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $151.20 | 2023-2025 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molham Aldeiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.